CHEMOPREVENTION TRIAL (TAMOXIFEN) IN PROLIFERATIVE BREAST DISEASE

增殖性乳腺疾病的化学预防试验（他莫昔芬）

• 批准号: 6245900
• 负责人: JOHN HARRIS WARD
• 金额: $ 2.15万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-06 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6245900
• 关键词: biomarker; breast neoplasm /cancer diagnosis; breast neoplasms; cancer prevention; cancer risk; chemoprevention; clinical research; clinical trials; female; human subject; human therapy evaluation; mammary disorder; preneoplastic state; tamoxifen

The aims of this study are: 1) to identify a group of women at high risk for breast cancer by detecting an intermediate marker, proliferative breast disease, in women with prior minimal cancer in one breast; and 2) to perform a short-term, placebo-controlled, randomized chemoprevention trial with Tamoxifen to evaluate its ability to modify proliferative breast disease.

本研究的目的是：1）确定一组妇女在高 乳腺癌的风险通过检测中间标记， 增生性乳腺疾病，在一个先前患有轻微癌症的女性中， 乳房;和2）进行短期，安慰剂对照，随机 他莫昔芬的化学预防试验，以评估其改变 乳腺增生病